| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating expenses: | ||||||||||||
Research and development | ||||||||||||
91,133 | 94,737 | 85,433 | 77,321 | 69,305 | 57,965 | 52,149 | 48,088 | 43,101 | 39,905 | 0 | 0 | 0 |
General and administrative | ||||||||||||
22,798 | 24,581 | 23,941 | 21,486 | 20,711 | 17,722 | 16,313 | 14,920 | 13,616 | 14,952 | 0 | 0 | 0 |
Restructuring charges | ||||||||||||
0 | - | - | - | - | - | - | - | - | - | - | - | - |
Total operating expenses | ||||||||||||
115,875 | 119,318 | 109,374 | 98,807 | 90,016 | 75,687 | 68,462 | 63,008 | 56,717 | 54,857 | 0 | 0 | 0 |
Loss from operations | ||||||||||||
-115,875 | -119,318 | -109,374 | -98,807 | -90,016 | -75,687 | -68,462 | -63,008 | -56,717 | -54,857 | 0 | 0 | 0 |
Other income (expense): | ||||||||||||
Revaluation of preferred unit tranche right | ||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | - |
Interest income | ||||||||||||
1,236 | 1,580 | 1,663 | 1,349 | 1,062 | 619 | 291 | 250 | 222 | 219 | 0 | 0 | 0 |
Other income | ||||||||||||
304 | 515 | 428 | 410 | 451 | 270 | 280 | 470 | 856 | 1,001 | 0 | 0 | 0 |
Total other income (expense), net | ||||||||||||
1,540 | 2,095 | 2,091 | 1,759 | 1,513 | 889 | 1,098 | 1,159 | 1,537 | 1,679 | 0 | 0 | 0 |
Net loss | ||||||||||||
-114,335 | -117,223 | -107,283 | -97,048 | -88,503 | -74,798 | -67,364 | -61,849 | -55,180 | -53,178 | 0 | 0 | 0 |
Net loss attributable to non-controlling interest | ||||||||||||
- | - | - | - | - | - | - | - | - | -1,060 | 0 | 0 | 0 |
Net loss attributable to Solid Biosciences Inc. | ||||||||||||
- | - | - | - | - | - | - | - | - | -52,118 | 0 | 0 | 0 |
Accretion of preferred units to redemption value | ||||||||||||
- | - | - | - | - | - | - | - | - | 959 | 0 | 0 | 0 |
Redemption of preferred units | ||||||||||||
- | - | - | - | - | - | - | - | - | 15,685 | 0 | 0 | 0 |
Redemption of redeemable interest from non-controlling interest in Solid GT | ||||||||||||
- | - | - | - | - | - | - | - | - | 1,925 | 0 | 0 | 0 |
Net loss attributable to common stockholders | ||||||||||||
- | - | - | - | - | - | - | - | - | -39,317 | 0 | 0 | 0 |
Net loss per share attributable to common stockholders, basic and diluted | ||||||||||||
-0.56 | -0.63 | -0.67 | -0.76 | -0.85 | -0.64 | -0.55 | -0.52 | -0.54 | -1.42 | -0.79 | -0.66 | -0.01 |
Weighted average shares of common stock outstanding, basic and diluted | ||||||||||||
48,059 | 48,069 | 43,467 | 34,843 | 34,776 | 34,706 | 34,539 | 34,449 | 29,354 | 17,412 | 17,096 | 17,041 | 3,047 |